slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
234,421-234,450 of 319,975
27
Uses a 2x2 grid layout to present four key performance indicators.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
28
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Beat · Financial Overview1 hit
29
This is a closing slide for an investor presentation.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Loop · Golden Circle1 hit
30
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations Loop · Golden Circle1 hit
31
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
32
The table includes a footnote regarding non-recurring share listing expenses.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
33
The table shows adjustments for share-based compensation and depreciation & amortization to arrive at non-IFRS metrics.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
34
The table provides a clear breakdown of non-cash and non-recurring items used to adjust the operating loss.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
35
The table shows a significant increase in operating loss in 2023, largely driven by share-listing expenses.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
36
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
37
The table details non-cash and non-recurring items to arrive at Adjusted EBITDA.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
38
Freightos | Investor Presentation Deck | 39 slidesFreightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
39
The slide uses a structured table to explain how network effects are being scaled.Freightos | Investor Presentation Deck | 39 slides · Freightos
Pitch deck Investor relations 1 hit
01
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
02
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
03
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
04
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Attention1 hit
05
The slide uses a Gantt-style visualization to show the progress of various drug candidates through clinical phases.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Need1 hit
06
Genprex | Investor Presentation Deck | 58 slidesGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Need1 hit
07
Includes a cytogenetic map showing the 600kb deletion region on chromosome 3.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · NeedLoop · Golden Circle1 hit
08
Uses a 'brake pedal' analogy to explain biological function.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · NeedLoop · Golden Circle1 hit
09
The slide uses a process diagram to illustrate the mechanism of action for REQORSA gene therapy.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · NeedLoop · Golden Circle1 hit
10
The process is presented as a sequential workflow.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
11
The slide uses a hub-and-spoke visual metaphor to connect the central platform to three key value propositions.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
12
The slide uses a numbered list format to explain the mechanism of action.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
13
The slide uses a line chart (Seahorse XF Glycolysis Stress Test profile) and a bar chart to show metabolic impact.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
14
The slide uses a series of circles to present key metrics, highlighting the global market size as the central focus.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
15
ONC-001 TrialGenprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
16
The slide uses fluorescence microscopy images to show the mechanism of action (selective uptake) of the drug.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
17
The trial met Simon 2-stage criteria but was discontinued to prioritize a study with Tagrisso.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit